Evidence map›Paper›PMID 36117569›Full record

ArticleContemporary clinical trials communications2022

Diminishing accelerated long-term forgetting in mild cognitive impairment: Study protocol for a prospective, double-blind, placebo-controlled, randomized controlled trial.

Katherine S Adcock, Brian Lawlor, Ian H Robertson, Sven Vanneste

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Contemporary clinical trials communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05289804 (Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05289804 phase1 / phase2completednot on this map

Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment: Study Protocol for a Prospective, Double-blind, Placebo-controlled, Randomized Controlled Trial

TypeinterventionalSponsorUniversity of Dublin, Trinity CollegeRan2022 to 2026Enrolled80ConditionsMild Cognitive Impairment, Memory Impairment, Memory Disorders in Old AgeArmsNITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation, Sham NITESGON
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Katherine S AdcockGlobal Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Brian LawlorGlobal Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Ian H RobertsonGlobal Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Sven VannesteGlobal Brain Health Institute, Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Trinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Harnessing the lifelong potential of the human brain for neuroplasticity may serve to maintain the viability of neural structures and postpone the onset of cognitive decline. The absence of effective pharmacological interventions to counter memory decline has encouraged scientists to test the possibility that noninvasive electrical stimulation may serve as an additional tool to improve memory abilities.Previous research showed that electrical stimulation of the greater occipital nerve enhances memory recall performance in young and older healthy subjects. This study aims to extend these findings to determine the effect of transcutaneous electrical stimulation of the greater occipital nerve on the improvement of episodic memory in individuals with amnestic Mild Cognitive Impairment (aMCI). Methods/design: This study is a prospective, double-blind, placebo-controlled, randomized parallel-group study. A total of 100 individuals with a diagnosis of aMCI according to NIA/AA will be recruited. Participants will be randomly assigned to one of four groups. One group will receive active non-invasive transcutaneous electrical stimulation of greater occipital nerve (NITESGON), while three groups will serve as controls (i.e., sham NITESGON, active NITESGON with local anesthesia, and active NITESGON on the C5/C6 nerve). The primary outcome, i.e., memory recall, will be determined by a word association task, and will be recorded at baseline, 7 days after NITESGON, and 28 days after NITESGON. The secondary outcome is neurophysiological changes determined by resting state EEG and will be assessed immediately before and after NITESGON. Discussion: The results will add new insights into improving episodic memory in individuals with aMCI. Trial registration: #NCT05289804 (clinicaltrial.gov). Protocol approval id: #SPREC102021-23 (Ethics Committee at Trinity College Dublin, School of Psychology).

Indexed as

Amnestic mild cognitive impairmentElectrical stimulationEpisodic memoryGreater occipital nerveMild Alzheimer's disease

Identifiers

PMID36117569
PMCPMC9478352
OpenAlexW4294203702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.